<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291108</url>
  </required_header>
  <id_info>
    <org_study_id>210669-013</org_study_id>
    <nct_id>NCT01291108</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared
      with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in
      patients with primary open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Eye IOP</measure>
    <time_frame>Baseline, Day 57</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes are used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Worse Eye IOP</measure>
    <time_frame>Baseline, Day 57</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. The worse eye IOP refers to eye with the worse baseline IOP, which is determined as the eye with the higher mean diurnal IOP at baseline. If both eyes have the same mean diurnal IOP at baseline, the right eye is designated as the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>AGN-210669</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-210669 + bimatoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-210669 + bimatoprost vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost + AGN-210669</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost + bimatoprost vehicle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210669</intervention_name>
    <description>AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.</description>
    <arm_group_label>AGN-210669</arm_group_label>
    <arm_group_label>AGN-210669 + bimatoprost</arm_group_label>
    <arm_group_label>AGN-210669 + bimatoprost vehicle</arm_group_label>
    <arm_group_label>bimatoprost + AGN-210669</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost</intervention_name>
    <description>bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.</description>
    <arm_group_label>AGN-210669 + bimatoprost</arm_group_label>
    <arm_group_label>bimatoprost</arm_group_label>
    <arm_group_label>bimatoprost + AGN-210669</arm_group_label>
    <arm_group_label>bimatoprost + bimatoprost vehicle</arm_group_label>
    <other_name>LUMIGAN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost vehicle</intervention_name>
    <description>bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.</description>
    <arm_group_label>AGN-210669 + bimatoprost vehicle</arm_group_label>
    <arm_group_label>bimatoprost + bimatoprost vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye

          -  Requires bilateral treatment with an IOP-lowering medication

          -  Best corrected visual acuity of 20/100 or better in each eye

        Exclusion Criteria:

          -  Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2
             months

          -  Inability to fast for up to 10 hours

          -  Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive
             keratectomy)

          -  Intraocular surgery or IOP-lowering laser surgery (eg, laser trabeculoplasty) within 6
             months

          -  Current or anticipated use of artificial tears or any ocular medications aside from
             study medications during study

          -  Anticipated wearing of contact lenses during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <results_first_submitted>August 13, 2013</results_first_submitted>
  <results_first_submitted_qc>November 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2013</results_first_posted>
  <disposition_first_submitted>October 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 17, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 23, 2012</disposition_first_posted>
  <last_update_submitted>November 4, 2013</last_update_submitted>
  <last_update_submitted_qc>November 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Pts were randomized at Baseline for the entire study. At Mo 1, pts received either AGN-210669 or bimatoprost. At Mo 2, pts who had received AGN-210669, then received either AGN-210669+bimatoprost or AGN-210669+bimatoprost vehicle and pts who had received bimatoprost, then received either bimatoprost+AGN-210669 or bimatoprost+bimatoprost vehicle.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AGN-210669</title>
          <description>AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.</description>
        </group>
        <group group_id="P2">
          <title>AGN-210669 + Bimatoprost</title>
          <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="P3">
          <title>AGN-210669 + Bimatoprost Vehicle</title>
          <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="P4">
          <title>Bimatoprost</title>
          <description>bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.</description>
        </group>
        <group group_id="P5">
          <title>Bimatoprost + AGN-210669</title>
          <description>bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="P6">
          <title>Bimatoprost + Bimatoprost Vehicle</title>
          <description>bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 1 (Monotherapy)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64">All patients who completed Month 1 were randomized to adjunctive therapy for Month 2.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="60">All patients who completed Month 1 were randomized to adjunctive therapy for Month 2.</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Month 2 (Adjunctive Therapy)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">All patients who completed Month 1 were randomized to adjunctive therapy for Month 2.</participants>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0">All patients who completed Month 1 were randomized to adjunctive therapy for Month 2.</participants>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AGN-210669 Followed by AGN-210669 + Bimatoprost</title>
          <description>AGN-210669 0.05% applied as 1 drop in each eye every evening for Month 1 followed by AGN-210669 0.05% + bimatoprost 0.03% applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
        </group>
        <group group_id="B2">
          <title>AGN-210669 Followed by AGN-210669 + Bimatoprost Vehicle</title>
          <description>AGN-210669 0.05% applied as 1 drop in each eye every evening for Month 1 followed by AGN-210669 0.05% + bimatoprost 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
        </group>
        <group group_id="B3">
          <title>Bimatoprost Followed by Bimatoprost + AGN-210669</title>
          <description>bimatoprost 0.03% applied as 1 drop in each eye every evening for Month 1 followed by bimatoprost 0.03% + AGN-210669 applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
        </group>
        <group group_id="B4">
          <title>Bimatoprost Followed by Bimatoprost + Bimatoprost Vehicle</title>
          <description>bimatoprost 0.03% applied as 1 drop in each eye every evening for Month 1 followed by bimatoprost 0.03% + bimatoprost 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Eye IOP</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes are used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
        <time_frame>Baseline, Day 57</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who had a baseline and at least 1 post-baseline IOP measurement</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-210669 Followed by AGN-210669 + Bimatoprost Vehicle</title>
            <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Followed by Bimatoprost + Bimatoprost Vehicle</title>
            <description>bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
          </group>
          <group group_id="O3">
            <title>Combined Adjunctives</title>
            <description>Combined adjunctives refer to the combined groups of ’AGN-210669 0.05% + bimatoprost’ and ’bimatoprost + AGN-210669 0.05%’. The first treatment is applied as 1 drop in each eye every evening for Month 1 followed by AGN-210669 0.05% + bimatoprost 0.03% applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Eye IOP</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes are used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
          <population>Modified Intent to Treat: all randomized and treated patients who had a baseline and at least 1 post-baseline IOP measurement</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.16" spread="2.169"/>
                    <measurement group_id="O2" value="25.98" spread="1.962"/>
                    <measurement group_id="O3" value="26.26" spread="2.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.91" spread="2.382"/>
                    <measurement group_id="O2" value="23.82" spread="2.301"/>
                    <measurement group_id="O3" value="23.85" spread="2.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.49" spread="1.338"/>
                    <measurement group_id="O2" value="22.35" spread="2.024"/>
                    <measurement group_id="O3" value="22.79" spread="2.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.48" spread="2.467"/>
                    <measurement group_id="O2" value="22.07" spread="2.596"/>
                    <measurement group_id="O3" value="21.73" spread="2.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 0 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="2.881"/>
                    <measurement group_id="O2" value="-10.28" spread="3.190"/>
                    <measurement group_id="O3" value="-10.84" spread="3.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 4 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.95" spread="2.503"/>
                    <measurement group_id="O2" value="-8.95" spread="3.531"/>
                    <measurement group_id="O3" value="-8.79" spread="3.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 8 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.57" spread="3.484"/>
                    <measurement group_id="O2" value="-7.19" spread="3.198"/>
                    <measurement group_id="O3" value="-7.67" spread="2.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 12 (n=16,17,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" spread="2.690"/>
                    <measurement group_id="O2" value="-6.87" spread="2.838"/>
                    <measurement group_id="O3" value="-6.03" spread="2.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Worse Eye IOP</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. The worse eye IOP refers to eye with the worse baseline IOP, which is determined as the eye with the higher mean diurnal IOP at baseline. If both eyes have the same mean diurnal IOP at baseline, the right eye is designated as the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
        <time_frame>Baseline, Day 57</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who had a baseline and at least 1 post-baseline IOP measurement</population>
        <group_list>
          <group group_id="O1">
            <title>AGN-210669 Followed by AGN-210669 + Bimatoprost Vehicle</title>
            <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Followed by Bimatoprost + Bimatoprost Vehicle</title>
            <description>bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
          </group>
          <group group_id="O3">
            <title>Combined Adjunctives</title>
            <description>Combined adjunctives refer to the combined groups of ’AGN-210669 0.05% + bimatoprost’ and ’bimatoprost + AGN-210669 0.05%’. The first treatment is applied as 1 drop in each eye every evening for Month 1 followed by AGN-210669 0.05% + bimatoprost 0.03% applied as 1 drop of each treatment in both eyes every evening for Month 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Worse Eye IOP</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. The worse eye IOP refers to eye with the worse baseline IOP, which is determined as the eye with the higher mean diurnal IOP at baseline. If both eyes have the same mean diurnal IOP at baseline, the right eye is designated as the worse eye. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). Data are recorded at Hours 0, 4, 8, and 12.</description>
          <population>Modified Intent to Treat: all randomized and treated patients who had a baseline and at least 1 post-baseline IOP measurement</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.56" spread="2.305"/>
                    <measurement group_id="O2" value="26.40" spread="2.069"/>
                    <measurement group_id="O3" value="26.61" spread="2.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.60" spread="2.754"/>
                    <measurement group_id="O2" value="24.25" spread="2.295"/>
                    <measurement group_id="O3" value="24.31" spread="2.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.04" spread="1.687"/>
                    <measurement group_id="O2" value="22.73" spread="2.290"/>
                    <measurement group_id="O3" value="23.17" spread="2.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.72" spread="2.811"/>
                    <measurement group_id="O2" value="22.47" spread="2.598"/>
                    <measurement group_id="O3" value="21.93" spread="2.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 0 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50" spread="2.989"/>
                    <measurement group_id="O2" value="-10.56" spread="3.435"/>
                    <measurement group_id="O3" value="-10.96" spread="3.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 4 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.38" spread="2.841"/>
                    <measurement group_id="O2" value="-9.16" spread="3.472"/>
                    <measurement group_id="O3" value="-9.01" spread="3.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 8 (n=24,25,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.94" spread="3.817"/>
                    <measurement group_id="O2" value="-7.42" spread="3.526"/>
                    <measurement group_id="O3" value="-7.92" spread="3.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 57-Hr 12 (n=16,17,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="2.696"/>
                    <measurement group_id="O2" value="-7.00" spread="2.969"/>
                    <measurement group_id="O3" value="-5.99" spread="3.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was used to assess adverse events (AEs) and serious adverse events (SAEs) and included all treated patients. SAEs and AEs are presented by treatment arm not necessarily by individual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>AGN-210669</title>
          <description>AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.</description>
        </group>
        <group group_id="E2">
          <title>AGN-210669 + Bimatoprost</title>
          <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="E3">
          <title>AGN-210669 + Bimatoprost Vehicle</title>
          <description>AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="E4">
          <title>Bimatoprost</title>
          <description>bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.</description>
        </group>
        <group group_id="E5">
          <title>Bimatoprost + AGN-210669</title>
          <description>bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
        <group group_id="E6">
          <title>Bimatoprost + Bimatoprost Vehicle</title>
          <description>bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Uveal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Thickening</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anterior Chamber Cell</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

